| Literature DB >> 33178834 |
Tsadkan Gebremeskel Haile1, Gereziher Gebremedhin Sibhat2, Ebisa Tadese1, Desta Tesfay1, Fantahun Molla1.
Abstract
Various species of the genus Grewia have been investigated for different pharmaceutical applications as excipients, yet a study on the potential use of Grewia ferruginea mucilage (class="Chemical">GFM) as a suspending agent is lacking. Thus, this study is aimed at evaluating the efficacy of Grewia ferruginea mucilage (Entities:
Mesh:
Substances:
Year: 2020 PMID: 33178834 PMCID: PMC7644311 DOI: 10.1155/2020/7612126
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Formulation ingredients of the metronidazole benzoate suspensions.
| Formula | MB | GFM | SCMC | XGM | MP | PP | T-80 | PG | SO | SS | S | DW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | % | % | % | % | % | % | % | |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| FA1 | 4 | 0.5 | — | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FA2 | 4 | 1 | — | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FA3 | 4 | 1.5 | — | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FA4 | 4 | 2 | — | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FB1 | 4 | — | 0.5 | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FB2 | 4 | — | 1 | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FB3 | 4 | — | 1.5 | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FB4 | 4 | — | 2 | — | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FC1 | 4 | — | — | 0.5 | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FC2 | 4 | — | — | 1 | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FC3 | 4 | — | — | 1.5 | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
| FC4 | 4 | — | — | 2 | 0.18 | 0.02 | 0.1 | 2 | 30 | 0.07 | 15 | 100 |
Key: MB: metronidazole benzoate; MP: methyl paraben; PP: propyl paraben; T-80: Tween 80; PG: propylene glycol; SO: sorbitol solution (70%); SS: sodium saccharine; S: sucrose; DW: distilled water; XGM: xanthan gum; GFM: Grewia ferruginea mucilage; and SCMC: sodium carboxymethyl cellulose; FA for GFM, FB for SCMC, and FC for XGM.
Figure 1FT-IR spectra of metronidazole benzoate standard (a) and mixture of Grewia ferruginea mucilage and metronidazole benzoate (b).
pH of metronidazole benzoate suspension formulations (n = 3, mean ± SD).
| Concentration of suspending agent (% | pH (mean ± SD) | ||
|---|---|---|---|
| GFM | SCMC | XGM | |
| 0.5 | 5.952 ± 0.28 | 6.311 ± 0.07 | 6.21 ± 0.014 |
| 1 | 5.790 ± 0.07 | 6.362 ± 0.14 | 5.90 ± 0.07 |
| 1.5 | 5.82 ± 0.07 | 6.365 ± 0.07 | 5.78 ± 0.07 |
| 2 | 5.721 ± 0.07 | 6.421 ± 0.07 | 5.70 ± 0.07 |
Flow rate of the suspension formulations at different suspending agent concentrations (n = 3, mean ± SD).
| Concentration of suspending agent (% | Flow rate (mL/sec) (mean ± SD) | ||
|---|---|---|---|
| GFM | SCMC | XGM | |
| 0.5 | 0.175 ± 0.0 | 0.516 ± 0.01 | 0.042 ± 0.02 |
| 1 | 0.042 ± 0.01 | 0.336 ± 0.01 | Viscous |
| 1.5 | Intermediate | 0.184 ± 0.0 | Viscous |
| 2 | Viscous | 0.047 ± 0.0 | Viscous |
Figure 2Apparent viscosities of suspensions prepared at different concentrations of suspending agents at a shear rate of 20 rpm (mean ± SD, n = 3).
Figure 3Apparent viscosity of suspension formulations prepared with suspending agents at a concentration of 0.5% w/v as a function of shear rate (mean ± SD, n = 3).
Average number of turns required to uniformly redisperse sediment of the suspensions after one week and one month.
| Suspending agent concentration (% | Rate of redispersibility (cycles) (mean ± SD) | |||||
|---|---|---|---|---|---|---|
| After a week | After a month | |||||
| GFM | SCMC | XGM | GFM | SCMC | XGM | |
| 0.5 | 16 ± 0.2 | 15 ± 0.01 | 13 ± 0.1 | 17 ± 0.2 | 16 ± 0.1 | 14 ± 0.21 |
| 1 | 14 ± 0.1 | 18 ± 0.1 | No | 15 ± 0.2 | 19 ± 0.11 | No |
| 1.5 | No | 20 ± 0.12 | No | No | 24 ± 0.12 | No |
| 2 | No | 26 ± 0.11 | No | No | 29 ± 0.13 | No |
Key: No: no need to redispersed.
Figure 4Sedimentation volumes (%) of metronidazole benzoate suspension formulations containing different concentrations of (a) GFM, (b) SCMC, and (c) XGM suspending agents, (n = 3, mean ± SD).
Figure 5Effect of different pH conditions on the sedimentation volumes (%) of metronidazole benzoate suspensions prepared using 0.5% w/v of suspending agents ((a) GFM, (b) SCMC, and (c) XGM) (mean ± SD, n = 3).
Figure 6The degree of flocculation of metronidazole benzoate suspension formulations containing 0.5% and 1.5% w/v suspending agents (mean ± SD, n = 3).
Figure 7Drug release profiles of metronidazole benzoate suspension formulations containing GFM (a) and SCMC (b) as suspending agent (n = 6, mean ± SD).
Physicochemical properties of metronidazole benzoate suspension formulations at time zero (Time-0) and after 3 months (Time-3) storage in different storage conditions (n = 3, mean ± SD).
| Formula | Storage | % of MB (mg/l) (mean ± SD, | pH | ||
|---|---|---|---|---|---|
| Time-0 | Time-3 | Time-0 | Time-3 | ||
| FA2 | 25°C/60% RH | 100.263 ± 3.964 | 100.276 ± 0.083 | 5.79 ± 0.07 | 5.70 ± 0.06 |
| 40°C/75% RH | 101.41 ± 0.05 | 99.208 ± 0.28 | 5.79 ± 0.07 | 5.16 ± 0.07 | |
| 4°C | 101.42 ± 0.318 | 100.17 ± 0.055 | 5.79 ± 0.07 | 5.8 ± 0.06 | |
| FB2 | 25°C/60% RH | 98.52 ± 0.093 | 98.47 ± 0.264 | 6.36 ± 0.14 | 6.5 ± 0.10 |
| 40°C/75% RH | 104.2 ± 0.18 | 100.05 ± 3.59 | 6.36 ± 0.14 | 5.9 ± 0.14 | |
| 4°C | 101.72 ± 0.009 | 97.74 ± 0.083 | 6.36 ± 0.14 | 6.5 ± 0.10 | |